Tracking CAR T cell therapy response and side effects using advanced technology
Monitoring CAR T Cell Therapeutic Response and Toxicity with Real-time, Label-free Cell Quantification
['FUNDING_R21'] · STANFORD UNIVERSITY · NIH-11116533
This study is working on a new way to keep track of CAR T cells in your blood during treatment for cancer or autoimmune diseases, using a special technology that helps doctors see how many of these important immune cells you have, so they can make your treatment safer and more effective.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11116533 on ClinicalTrials.gov |
What this research studies
This research focuses on improving CAR T cell therapy, a treatment for cancer and autoimmune diseases, by developing a new method to monitor the quantity of CAR T cells in a patient's blood. The approach utilizes surface enhanced Raman spectroscopy (SERS) combined with machine learning to provide real-time, cost-effective quantification of these immune cells. By accurately tracking CAR T cell levels, the research aims to enhance treatment efficacy and quickly identify potential toxicities. This innovative technique could lead to better patient management during therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients undergoing CAR T cell therapy for cancer or autoimmune diseases.
Not a fit: Patients who are not receiving CAR T cell therapy or those with conditions unrelated to the targeted therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective monitoring of CAR T cell therapies, improving patient outcomes and safety.
How similar studies have performed: Previous research has shown promise in using advanced imaging and quantification techniques in immunotherapy, indicating potential success for this novel approach.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DIONNE, JENNIFER A. — STANFORD UNIVERSITY
- Study coordinator: DIONNE, JENNIFER A.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anti-cancer therapy, anticancer immunotherapy, Autoimmune Diseases, autoimmune disorder